Aim: To explain the components of pharmaceutical expenditure and illustrate the strengths and limitations of this indicator. In particular, we explore policies applied in European countries that affect the price and volume of medicines. Methodology: This paper is based on a presentation held at the European Drug Utilization Research Group (EuroDURG)/International Society for Pharmacoepidemiology (ISPE)
No takes yet. Share an insight, caveat, or question.
Vogler et al. (2013) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: